Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26697559 | 1.00 | FFAR4 (0.42) | FFAR4FFAR1GPR84FAAHNFKB1 | |
| SCHEMBL26697565 | 1.00 | FFAR4 (0.42) | FFAR4FFAR1GPR84FAAHNFKB1 | |
| SCHEMBL16829966 | 1.00 | FFAR4 (0.42) | FFAR4FFAR1GPR84FAAHNFKB1 | |
| SCHEMBL26697626 | 0.98 | FFAR4 (0.40) | FFAR4FFAR1GPR84FAAHNFKB1 | |
| SCHEMBL16829715 | 0.97 | FFAR4 (0.42) | FFAR4FFAR1GPR84FAAHNFKB1 | |
| SCHEMBL16829802 | 0.93 | FFAR4 (0.42) | FFAR4FFAR1GPR84FAAHNFKB1 | |
| SCHEMBL16830092 | 0.93 | FFAR4 (0.42) | FFAR4FFAR1GPR84FAAHNFKB1 | |
| SCHEMBL8839011 | 0.93 | FFAR4 (0.42) | FFAR4FFAR1GPR84FAAHNFKB1 | |
| SCHEMBL16826320 | 0.93 | FFAR4 (0.42) | FFAR4FFAR1GPR84FAAHNFKB1 | |
| SCHEMBL29259417 | 0.93 | FFAR4 (0.42) | FFAR4FFAR1GPR84FAAHNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041441-A1 | NANOMATERIALS | BEAM THERAPEUTICS INC. | 2025-02-06 | — | — | US | disclosed |
| US-12059477-B2 | Nanomaterials | BEAM THERAPEUTICS INC. (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4281050-A1 | NANOMATERIALS | Beam Therapeutics Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-116761888-A | Nanomaterial for the preparation of a nanoparticle | 比姆医疗股份有限公司 | 2023-09-15 | — | — | CN | disclosed |
| US-20220249693-A1 | NANOMATERIALS | BEAM THERAPEUTICS INC. | 2022-08-11 | — | — | US | disclosed |
| WO-2022159463-A1 | NANOMATERIALS | BEAM THERAPEUTICS INC. (US) | 2022-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12059477-B2 | Nanomaterials | CD63, LIPA, PLIN3 | FFAR4 2652/4885FFAR1 2552/4885GPR84 4859/4885 |
| US-20220249693-A1 | NANOMATERIALS | CD63, LIPA, PLIN3 | FFAR4 2652/4885FFAR1 2552/4885GPR84 4859/4885 |
| US-20250041441-A1 | NANOMATERIALS | CD63, LIPA, PLIN3 | FFAR4 2652/4885FFAR1 2552/4885GPR84 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.